News
“Immunotherapy in neonatology and pediatrics” educational seminars in Almaty and Astana
26 FebruaryThe educational seminars for physicians on the topic of “Immunotherapy in neonatology and pediatrics” were held in children’s city hospitals of Almaty and Astana with support of the Ministry of Health local departments on February 25-26, 2015.
The seminars were organized by “VIVA Pharm” LLP in cooperation with Biotest AG (Germany).
The speakers were both local specialists: Zhubanysheva K.B., PhD, Chief freelance neonatologist of the MoH of the Republic of Kazakhstan (Astana), Aubakirova A.K., PhD, Head of Neonatology Chair of Kazakh Medical University of Continuing Education (KazMUCE, Almaty), and also foreign colleagues: Beloborodov V.B., Professor, Head of Infection disease Chair of Russian Medical Academy of Postdiploma Education (RMAPE), Vice Chairman of Alliance of Clinical Chemotherapists and Microbiologists, and J. Voehreinger, Head of Intensive Care Department of Biotest AG (Germany).
About 150 Kazakh neonatologists and pediatric physicians who attended the seminars in Almaty and Astana cities, had a chance to get familiar with the results of international researches and practical application of immunoglobulins in the treatment of sepsis and cytomegalovirus infection.
On the worldwide level, an understanding of the need of use of adequate immunotherapy by immunoglobulins for the treatment of sepsis and cytomegalovirus infection appeared relatively recently. In this regard, the opportunity for Kazakh doctors in getting up-to-date information from leading experts was very timely and necessary.
The medicinal products of Pentaglobin and NeoCytotect, produced by Biotest AG, Germany, which presented on Kazakhstan market by VIVA Pharm LLP, are used in Europe as first choice treatment products for immunotherapy of sepsis and cytomegalovirus infection.
Thus, through educational activities and cooperation with leading international companies, VIVA PHARM makes its feasible contribution not only to the effectiveness of treatment and, accordingly, optimization of the state budget expenses, but also in mortality reduction in the Republic of Kazakhstan in general.
